

Supplementary Online Content

Mantri S, Fullard M, Gray SL, et al. Patterns of dementia treatment and frank prescribing errors in older adults with Parkinson disease. *JAMA Neurol*. Published online October 1, 2018. doi:10.1001/jamaneurol.2018.2820

eTable 1. Anticholinergic Burden Score

eTable 2. Demographic Characteristics Associated with Specific Dementia Drug Use Among Medicare Beneficiaries with Parkinson Disease, 2014

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Anticholinergic Burden Score		
Drugs with ACB Score 1	Drugs with ACB Score 2	Drugs with ACB Score 3
Alimemazine	Amantadine	Amitriptyline
Alverine	Belladonna	Amoxapine
Alprazolam	Carbamazepine	Atropine
Aripiprazole	Cyclobenzaprine	Benztropine
Asenapine	Cyproheptadine	Brompheniramine
Atenolol	Loxapine	Carbinoxamine
Bupropion	Meperidine	Chlorpheniramine
Captopril	Methotrimeprazine	Chlorpromazine
Cetirizine	Molindone	Clemastine
Chlorthalidone	Nefopam	Clomipramine
Cimetidine	Oxcarbazepine	Clozapine
Clidinium	Pimozide	Darifenacin
Clorazepate		Desipramine
Codeine		Dicyclomine
Colchicine		Dimenhydrinate
Desloratadine		Diphenhydramine
Diazepam		Doxepin
Digoxin		Doxylamine
Dipyridamole		Fesoterodine
Disopyramide		Flavoxate
Fentanyl		Hydroxyzine
Furosemide		Hyoscyamine
Flovoxamine		Imipramine
Haloperidol		Meclizine
Hydralazine		Methocarbamol

Hydrocortisone		Nortriptyline
lloperidone		Olanzapine
Isosorbide		Orphenadrine
Levocetirizine		Oxybutynin
Loperamide		Paroxetine
Loratidine		Perphenazine
Metoprolol		Procyclidine
Morphine		Promethazine
Nifedipine		Propantheline
Paliperidone		Propiverine
Prednisone		Quetiapine
Quinidine		Scopolamine
Ranitidine		Solifenacin
Risperidone		Thioridazine
Theophylline		Tolterodine
Trazodone		Trifluoperazine
Triamterene		Trihexyphenidyl
Venlafaxine		Trimipramine
Warfarin		Trospium
Campbell, N.L., Maidment, I., Fox, C., Khan, B. and Boustani, M. (2013). The 2012 update to the anticholinergic cognitive burden scale. Journal of the American Geriatrics Society, 61 (S1), S142-S143.		

eTable 2. Demographic Characteristics Associated with Specific Dementia Drug Use* Among Medicare Beneficiaries with Parkinson Disease, 2014

Characteristic		Donepezil	Rivastigmine	Galantamine	Memantine	Donepezil + memantine	Rivastigmine + memantine
		AOR (95%CI)	AOR (95%CI)	AOR (95%CI)	AOR (95%CI)	AOR (95%CI)	AOR (95%CI)
Race/ Ethnicity	White	1.00	1.00	1.00	1.00	1.00	1.00
	black	1.27 (1.19-1.35)	0.80 (0.75-0.86)	0.67 (0.55-0.83)	1.06 (1.0-1.12)	1.22 (1.13-1.31)	0.87 (0.77-0.97)
	other/unknown	0.87 (0.78-0.97)	0.99 (0.88-1.13)	0.83 (0.59-1.18)	1.12 (1.03-1.29)	0.92 (0.80-1.07)	1.00 (0.82-1.24)
	Asian	1.01 (0.93-1.12)	0.98 (0.89-1.09)	0.52 (0.37-0.74)	1.03 (0.94-1.12)	1.01 (0.90-1.13)	0.80 (0.67-0.95)
	Hispanic	0.84 (0.77-0.91)	0.98 (0.89-1.09)	0.59 (0.44-0.80)	1.42 (1.31-1.53)	1.14 (1.03-1.26)	1.38 (1.22-1.57)
	North American native	1.04 (0.76-1.44)	0.89 (0.62-1.27)	0.61 (0.19-1.92)	0.84 (0.59-1.13)	0.79 (0.52-1.21)	0.93 (0.53-1.64)
Sex	male	1.00	1.00	1.00	1.00	1.00	1.00
	female	0.97 (0.95-1.01)	0.97 (0.94-1.00)	0.84 (0.77-0.92)	1.08 (1.05-1.11)	1.05 (1.01-1.09)	1.00 (0.51-1.06)
Age	65-69 (ref)	1.00	1.00	1.00	1.00	1.00	1.00
	70-74	1.0 (0.96-1.10)	1.02 (0.95-1.10)	1.17 (0.95-1.44)	1.13 (1.06-1.21)	1.19 (1.09-1.30)	1.14 (1.01-1.30)

	75-79	0.97 (0.91- 1.03)	1.05 (0.98- 1.12)	1.23 (1.01- 1.50)	1.24 (1.16- 1.32)	1.24 (1.14- 1.35)	1.31 (1.17- 1.48)
	80-84	1.00 (0.93- 1.06)	0.99 (0.93- 1.07)	1.14 (0.93- 1.38)	1.33 (1.25- 1.42)	1.35 (1.24- 1.46)	1.31(1.16 -1.47)
	85+	1.01 (0.95- 1.08)	0.88 (0.83- 0.95)	1.25 (1.03- 1.52)	1.38 (1.30- 1.47)	1.42 (1.31- 1.54)	1.18 (1.05- 1.32)

* As measured by presence of a prescription fill from January 1, 2014-December 31, 2014. The categories are not mutually exclusive, a beneficiary could have more than one medication prescribed over the course of the year.

Statistically significant estimates are in bold.